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Abstract A number of equivalent-skin models are
available for investigation of the ex vivo effect of topical
application of drugs and cosmaceuticals onto skin, however
many have their drawbacks. With the March 2013 ban on
animal models for cosmetic testing of products or ingre-
dients for sale in the EU, their utility for testing toxicity
and effect on skin becomes more relevant. The aim of this
study was to demonstrate proof of principle that altered
expression of key gene and protein markers could be
quantified in an optimised whole tissue biopsy culture
model. Topical formulations containing green tea catechins
(GTC) were investigated in a skin biopsy culture model
(n = 11). Punch biopsies were harvested at 3, 7 and
10 days, and analysed using qRT-PCR, histology and
HPLC to determine gene and protein expression, and
transdermal delivery of compounds of interest. Reduced
gene expression of a-SMA, fibronectin, mast cell tryptase,
mast cell chymase, TGF-b1, CTGF and PAI-1 was
observed after 7 and 10 days compared with treated con-
trols (p\ 0.05). Histological analysis indicated a reduction
in mast cell tryptase and chymase positive cell numbers in
treated biopsies compared with untreated controls at day 7
and day 10 (p\ 0.05). Determination of transdermal
uptake indicated that GTCs were detected in the biopsies.
This model could be adapted to study a range of different
topical formulations in both normal and diseased skin,
negating the requirement for animal models in this context,
prior to study in a clinical trial environment.
Keywords Skin scarring  Dermal delivery  Extracellular
matrix  Mast cells  Inflammation  Dermatology
Abbreviations
GTE Green tea extract
GT Green tea catechins
ECM Extracellular matrix
a-SMA a-smooth muscle actin
TGF-b1 Transforming growth factor-b1
CTGF Connective tissue growth factor
PI3-K Phosphatidylinositide 3-kinase
PAI-1 Plasminogen activator inhibitor-1
STAT3 Signal transducer and activator of transcription 3
MMP-3 Matrix metalloproteinase-3
RPL32 Ribosomal protein L32
Introduction
A range of different models exist for studying the effect of
drugs and cosmaceuticals, both in vitro and in vivo.
However, studying the effect of drug and cosmaceutical
compounds can be challenging. In March 2013, the use of
animal models for cosmetic testing of products or
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ingredients for sale in the EU was banned [32]. Animal
models were not perfect; mice, rat and rabbit models in
particular are limited as they do not accurately represent
the structure of human skin, the best current model in terms
of dermal structure and underlying mechanisms is the pig
[16, 35, 44]. The field of dermocosmetics and our increased
knowledge about the architecture of skin has led to an
enhancement and refinement of a number of in vitro,
in vivo and in silico techniques to aid skin research, [9, 11]
which can be adapted to study a range of conditions in
order to more accurately study both human skin disease
[34] and aid drug development [28].
Whilst in vitro models have their benefits, they are not
without their drawbacks. Two dimensional cell culture
models do not represent the interactions and mechanisms
present in whole skin, such as the effect of the extracellular
matrix (ECM) in terms of structure, as well as cell sig-
nalling mechanisms and the processes of metabolism [18].
The incorporation of skin appendages such as hair follicles
and sweat glands is an added complication [28]. It is also
more challenging to model the effects of dermal absorp-
tion; while keratinocytes in air exposed culture can dif-
ferentiate and form layers and produce a stratum corneum,
this is not representative of normal skin structure [22]. Ex
vivo human skin tissue is more appropriate for certain
types of research; use of whole skin biopsies in culture
allows the effect of individual ingredients and formulations
to be tested in an environment more closely mimicking
normal skin [33].
In this study, five unique cream formulations and con-
trols containing different quantities and proportions of
green tea catechins (GTC) were assessed, in order to val-
idate and optimise a normal skin tissue biopsy organ cul-
ture model already established in our laboratory [12, 1,
[27]. The effect of these formulations at the gene and
protein expression level was assessed, as well as mast cell
numbers, which are linked with inflammation and
increased in a range of dermatological conditions [3, 17,
23, 26, 30, 39]. The level of transdermal green tea extract
delivery was also analysed using a previously published
method [2], to interpret in vitro effect in a whole tissue
biopsy culture model in normal skin.
Materials and methods
Tissue samples
Normal skin tissue samples (n = 11) were obtained by the
Skin and Tissue Bank (North West Research Ethics
Committee Ref 11/NW/0683). Patients were recruited and
samples obtained following informed consent prior to
elective cosmetic surgery, and were anonymised and coded
prior to use. Samples were stored and transported at 4 C in
Dulbecco’s Modified Eagle Medium (DMEM) and pro-
cessed for whole tissue organ culture within 24 h of
excision.
Organ culture model
The normal skin organ culture was based on the method-
ology of Lu et al. [27]. Six millimetre punch biopsies of
normal skin were added to a 24-well plate containing
transwell inserts, allowing the biopsy to be suspended in
liquid culture media whist keeping the epidermis separate
and exposed to air for the addition of topical treatments
(Fig. 1). Supplemented serum free Williams E culture
media was used (1 % penicillin/streptomycin, 1 % L-glu-
tamine, 1 % non-essential amino acid solution, 1 %
ITS ? 3, and 10 ng/ml hydrocortisone), 500 ll of media
was added to each well and was changed daily. Antibiotics
were used in order to prevent contamination by the
microflora naturally present on human skin. The culture
model was maintained in an incubator under standard
conditions (37 C, 5 % CO2).
For long term culture assessment, 5 ll of each topical
formulation was added daily to the epidermal region of
each punch biopsy (n = 6). Five different cream formula-
tions and controls were used (Table 1). Eucerin cream
containing 10 % Urea (Eucerin, Germany) was used as a
control cream; this is a common over the counter mois-
turiser used across a range of dermatological conditions to
reduce itch and inflammation. The organ culture was
maintained for 3, 7 or 10 days, upon which biopsies were
removed and washed with PBS to remove any remaining
cream from the stratum corneum. Biopsies were either
fixed in formalin and embedded in wax for histological
analysis, or stored in RNA later at -80 C prior to mRNA
extraction and quantification.
Transdermal delivery quantification
A second set of short term culture experiments were per-
formed, in order to assess of transdermal delivery, the normal
skin organ culture model was set up as described (n = 5),
and left to establish for 48 h (see also Fig. 1). One 5 ll of
Cream A, containing GTC, was added to the epidermal
region, and biopsies were removed at time points over a
further 48 h period. The biopsies were washed in 500 ll of
citrate phosphate buffer (18.1 g Na2HPO412H2O, 9.42 g
citric acid, 1 ml TFA in 1 L de-ionised water, adjusted to pH
5.5 with concentrated NaOH), then snap frozen in liquid
nitrogen and stored at -80 C for analysis of uptake of
components of GTE. The citrate phosphate wash buffer and
culture media were also retained at each time point and
stored at -80 C for analysis.
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Analysis of gene expression
The expression of mRNA from organ culture punch
biopsy samples was assessed. The mRNA was extracted
using Qiagen Qiashredder and RNAeasy mini prep kits
(as per manufacturer’s protocol) and samples were stored
at -80 C prior to use. The concentration of mRNA
obtained was quantified using a nanodrop 2000 prior to
conversion into cDNA. Samples were analysed using the
Roche qRT-PCR Lightcycler 480 platform with RPL32
gene expression used for quantification and standardisa-
tion of results. A list of primers and sequences used is
shown in Table 2.
Histology
Slides were prepared from wax embedded whole tissue
blocks using a Leica microtome and left to dry, with
consecutive tissue sample in duplicate on each slide. Slides
were dewaxed with xylene and ethanol and rehydrated.
Antigen retrieval was performed using citrate buffer, pH 6,
for 60 min in a water bath at 60 C. Immunofluorescence
slides were washed with PBS/0.01 % Tween 20 and
blocked with 2 % BSA in PBS prior to addition of primary
antibodies (Abcam, Cambridge UK). After incubation
overnight at 4 C, slides were washed with TBS buffer
containing 0.05 % Triton X100 followed by addition of
secondary antibody (Life Technologies, Paisley UK).
Slides were counterstained with DAPI, mounted and stored
at -20 C prior to analysis. Immunohistological slides
were prepared according to the Leica novolink peroxidise
staining kit protocol (Milton Keynes, UK), with overnight
incubation of primary antibody at 4 C, and development
of peroxidase staining with DAB chromogen reagent for
5 min. Slides were also prepared and stained with
haematoxylin and eosin in order to assess morphological
and histological changes in the punch biopsies in culture
over time. All tissue sections were stained and prepared in
the same batch in order to reduce variability.
HPLC determination of green tea derived
compounds in the organ culture model
HPLC determination of uptake of GTC derived compounds
was undertaken, based on the methodology of Batchelder
et al. [2]. In brief, an Agilent 1100 system was utilised and
data analysis undertaken using chemstation software. The
column used was a Phenomenex Sphereclone (5 lm ODS,
4.6 9 250 mm), with a mobile phase of 0.1 % TFA:Ace-
tonitrile in the ratio of 87:13. The flow rate was set at
1.0 ml/min with no gradient, 50 ll of each sample was run
for 40 min and detection of the major catechins found in
green tea, (-)-epicatechin (EC), (-)-epigallocatechin (EGC),
(-)-epicatechin gallate (ECG) and (-)-epigallocatechin
gallate (EGCG) was undertaken at 210 nm (Fig. 2). Cali-
bration curves of pure catechins dissolved in DMSO were
prepared, diluted in citrate phosphate buffer.
To test for transdermal uptake of green tea catechins,
tissue samples stored at -80 C were defrosted and sepa-
rated finely minced with a scalpel. 500 ll of citrate phos-
phate buffer was added to each tissue fragment, which was
then lysed in a tissue lyser for 2 min. After 60 min incu-
Fig. 1 A diagram and flow
chart depicting the organ culture
methodology, and the
experimental approach used in
this study
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bation, samples were centrifuged and the supernatant
quantified on the HPLC. Culture media was also analysed
to test for catechin concentrations, as was the wash buffer
used to wash the tissue samples prior to storage.
Statistics and data analysis
Analysis of PCR data was undertaken in Microsoft Excel,
utilising the Paired Student’s T Test to define significance as
p\ 0.05. PCR data was expressed as fold change, via
2-(DDCT). Analysis of histological data was performed using
Definiens Tissue Studio (Definiens AG, Munich, Germany),
in order to quantify the amount of staining present. For each
batch of microscope slides, whole sections of stained tissue
in duplicate were scanned, with exposure settings stan-
dardised in order to eliminate variability.
Results
Analysis of gene expression
In the long term organ culture experiments, gene expres-
sion was determined after 3, 7 and 10 days, treated daily
with the five cream formulations (n = 6). An untreated
biopsy taken at day 0 was used as a starting control, with
the untreated biopsies and treated control biopsies taken
from the organ culture model used as internal controls.
mRNA expression between day 0 and later time points was
reduced by approximately tenfold (p\ 0.001), due to the
fact that the tissue biopsies in culture are no longer actively
proliferating. The PCR data comparing cream A and cream
C were broadly similar (Fig. 3), however there were some
differences, in particular with collagen I, fibronectin, TGF-
Table 1 List of the active ingredients included in the various treatments
Cream name Active ingredients
A—cream formulation 1: green tea extract Aqua, Dipropylene Glycol Dipelargonate, Caprylic/Capric Triglyceride, Glycerin,
Cyclopentasiloxane, Cetyl Alcohol, Cetearyl Alcohol, Phenoxyethanol, Glyceryl
Stearate, Peg-75 Stearate, Ceteth-20, Steareth-20, Poloxamer 235, Poloxamer 338,
Ethoxydiglycol, Xanthan Gum, Camellia Sinensis Extract, Butylene Glycol,
Tocophersolan, Tocopherol, Maltodextrin, Triethanolamine, Acrylates/C10-30 Alkyl
Acrylate Crosspolymer, Ethylhexylglycerin, Helianthus Annuus Seed Oil, Lecithin,
Hydrolyzed Algin, Maris Aqua, Chlorella Vulgaris Extract, Magnolia Officinalis
Bark Extract, Vitis Vinifera Seed Extract
B—base cream formulation 1: (control) Aqua, Dipropylene Glycol Dipelargonate, Caprylic/Capric Triglyceride, Glycerin,
Cyclopentasiloxane, Cetyl Alcohol, Cetearyl Alcohol, Phenoxyethanol, Glyceryl
Stearate, Peg-75 Stearate, Ceteth-20, Steareth-20, Poloxamer 235, Poloxamer 338,
Ethoxydiglycol, Xanthan Gum, Butylene Glycol, Tocophersolan, Tocopherol,
Maltodextrin, Triethanolamine, Acrylates/C10-30 Alkyl Acrylate Crosspolymer,
Ethylhexylglycerin, Helianthus Annuus Seed Oil, Lecithin, Hydrolyzed Algin, Maris
Aqua, Chlorella Vulgaris Extract, Magnolia Officinalis Bark Extract, Vitis Vinifera
Seed Extract
C—cream formulation 2: green tea extract Aqua, Glycerin, Olus (vegetable) oil, Rosa Canina Fruit Oil, Triticum Vulgare, (Wheat)
Germ Oil, Epigallocatechin Gallate, Cera Alba, Glyceryl Stearate, Citrate, Cetearyl
Alcohol, Glyceryl Caprylate, Benzyl Alcohol, Salicylic, Acid, Glycerin, Sorbic Acid,
Allantoin, Xanthan Gum, Arginine, Aloe Barbadensis Leaf Juice, Tocopherol,
Sodium Hyaluronate
D—base cream formulation 2: (control) Aqua, Glycerin, Olus (vegetable) oil, Rosa Canina Fruit Oil, Triticum Vulgare, (Wheat)
Germ Oil, Cera Alba, Glyceryl Stearate Citrate, Cetearyl, Alcohol, Glyceryl Caprylate,
Benzyl Alcohol, Salicylic Acid, Glycerin, Sorbic Acid, Allantoin, Xanthan Gum,
Arginine, Aloe Barbadensis Leaf Juice, Tocopherol, Sodium Hyaluronate
Cream E: Eucerin (10 % urea) control cream—
commercially available moisturizer
Aqua, Benzyl Alcohol, Caprylic/Capric Triglyceride, Dimethicone, Glycerin,
Hydrogenated Castor Oil, Isopropyl Palmitate, Lactic Acid, Magnesium, Sulfate,
Methoxy PEG-22-Dodecyl Glycol Copolymer, Octyldodecanol, Ozokerite, Cera
Microcristallina, PEG-2 Hydrogenated Castor Oil, PEG-45 Dodecyl Glycol, Copolymer,
PEG-7 Hydrogenated Castor Oil, Sodium Lactate, Sorbitan, Isostearate, Urea
Untreated control No topical treatment
Cream A and B were the same formulation, with cream A containing the active ingredients and cream B being the base cream control
Cream C and D were a different formulation, with cream C containing the active ingredient and cream D being the base cream control. Two
further controls were included—Cream E was Eucerin (10 % Urea) moisturiser, and a further set of biopsies which were untreated. Active
ingredients are indicated in bold
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b1 and a-SMA, related to the additional active components
in the cream A formulation.
For cream A, at Day 3 mast cell tryptase (p\ 0.01),
mast cell chymase (p\ 0.01), TGF-b1 (p\ 0.001) and
STAT-3 (p\ 0.001) were increased compared with cream
E control (Eucerin), whereas CTGF was reduced
(p\ 0.01). PAI-1 (p\ 0.05) and MMP-3 (p\ 0.001)
were reduced compared with cream B control, but PAI-1
was increased compared with untreated control (p\ 0.01).
a-SMA was increased compared to cream B (p\ 0.01) and
Eucerin (p\ 0.05) controls.
At Day 7, mast cell tryptase was increased compared
with untreated control (p\ 0.05), but reduced compared
with cream B (control) (p\ 0.05). PI3-K (p\ 0.05),
CTGF (p\ 0.05) and MMP-3 (p\ 0.01) were reduced
compared to cream E control. PAI-1 (p\ 0.001) and P13-k
(p\ 0.05) were reduced compared with cream B control.
CTGF (p\ 0.05), PAI-1 (p\ 0.01) and PI3-K (p\ 0.05)
were increased compared to untreated control.
At Day 10, mast cell tryptase (p\ 0.01), PI3-K
(p\ 0.001), PAI-1 (p\ 0.001), and MMP-3 (p\ 0.05)
were reduced compared with cream B (control), whereas
fibronectin was increased (p\ 0.01). Fibronectin was
reduced compared to untreated control (p\ 0.01) whereas
PA3-K was increased (p\ 0.001). Collagen 1 expression
was increased compared with cream B (p\ 0.01). CTGF
(p\ 0.001), MMP-3 (p\ 0.05) and PI3-K (p\ 0.001)
were increased compared with untreated controls, and
TGF-b1 (p\ 0.01), CTGF (p\ 0.001), STAT-3
(p\ 0.05) and PI3-K (p\ 0.05) were increased compared
with cream E control. a-SMA was increased compared to
all controls (p\ 0.01).
For cream C, at Day 3 a-SMA and STAT-3 was reduced
compared to untreated control (p\ 0.05), with TGF- b1
PAI-1 and STAT-3 reduced compared with cream D
(p\ 0.05). At Day 7 mast cell chymase (p\ 0.05), col-
lagen I (p\ 0.001), CTGF (p\ 0.001), PI3-K
(p\ 0.001), PAI-1 (p\ 0.001) and MMP-3 (p\ 0.01)
were reduced compared with cream D (control). collagen 1
(p\ 0.001), CTGF (p\ 0.05) and MMP-3 (p\ 0.001)
were also reduced compared with cream E control, with
Fibronectin (p\ 0.05), a-SMA (p\ 0.001), TGF-b1
(p\ 0.05) and STAT-3 (p\ 0.05) reduced compared with
all controls. CTGF (p\ 0.001), PI3-K (p\ 0.001) and
PAI-1(p\ 0.01) were increased compared to untreated
control.
At Day 10, mast cell tryptase was reduced compared
with cream D (control) (p\ 0.05). Fibronectin was
reduced compared with all controls (p\ 0.05) whereas
CTGF was increased (p\ 0.05). TGF-b1 was reduced
Table 2 A list of PCR primers used in this study, along with the
Roche probe ID
Primers Sequence Probe
Collagen I
L ctgtacgcaggtgattggtg 15
R atgttcagctttgtggacctc 15
Fibronectin
L gccactggagtctttaccaca 64
R cctcggtgttgtaaggtgga 64
a-SMA
L ctgttccagccatccttcat 58
R tcatgatgctgttgtaggtggt 58
TGF-b1
L agtggttgagccgtggag 68
R tgcagtgtgttatccctgct 68
MC Triptase
L gcgatgtggacaatgatgag 6
R tccattatggggaccttcac 6
MC Chymase
L acggaactttgtgctgacg 4
R ggctccaagggtgactgtta 4
CTGF
L ccgtactcccaaaatctcca 71
R ttagctcggtatgtcttcatgc 71
PI3-K
L ttgactttgaggtagtccagacc 71
R aaaagtgtccctgttgattcttct 71
PAI-1
L aaactccctagtctccacctga 14
R ccttaagggagttgtgcttca 14
STAT3
L tgatgcagtttggaaataatgg 18
R catgtcaaaggtgagggactc 18
MMP-3
L caaaacatatttctttgtagaggacaa 36
R ttcagctatttgcttgggaaa 36
RPL32
L gaagttcctggtccacaacg 17
R gagcgatctcggcacagta 17
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Fig. 2 The chemical structures
and molecular weights of the
four main green tea catechins
(GTCs), (-)-epicatechin (EC),
(-)-epigallocatechin (EGC),
(-)-epicatechin gallate (ECG)
and (-)-epigallocatechin gallate
(EGCG)
Fig. 3 Comparison of fold change in gene expression in the organ
culture models treated with cream A (top row) and cream C (bottom
row) after 3, 7 and 10 days (First, second and third columns,
respectively) compared with the treated and untreated controls, as
indicated in the key. (Statistical significance as derived from the
students T test indicated as *p\ 0.05, **p\ 0.01, ***p\ 0.001)
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compared with untreated control (p\ 0.05) and MMP-3
reduced compared with cream E control (p\ 0.01). PI3-K
was increased compared with untreated control (p\ 0.001)
and cream E control (p\ 0.05).
Detection of green tea catechin uptake
Peaks were observed for EGC, EC, EGCG and ECG at
retention times of 5.5, 11.3, 13.1 and 37.0 min respec-
tively, when pure compound was dissolved in DMSO and
then diluted with citrate phosphate buffer. Each peak was
individually resolved (Fig. 4a, ECG peak at 37 min not
shown due to scale). A full EGCG calibration curve is
shown in Fig. 4b, calibration curves were generated for all
four green tea catechins as EGCG is metabolized to EGC
and ECG metabolized to EC [40] (GTCs as previously
defined in Fig. 2). Calibration curves were reproducible
and linear for each compound over the range 0.1–10 lg/ml,
with R2 values[0.99 %, indicating a strong relationship
between peak area and concentration (Fig. 4c).
The cream A formulation were assessed to see precisely
how much of each particular catechin was present. 5 ll of
cream A was dissolved in 500 ll citrate phosphate buffer
(1:100 dilution) and run as a standard (in quintuplet from 5
separate runs), which contained on average 21.2 mg/ml of
EGCG, with a coefficient of variation of 10.2 %. EC was
detected at 0.67 mg/ml, and EGC and ECG both detected
at a low level (0.08 and 0.10 mg/ml respectively).
When whole tissue biopsies treated with one dose of
5 ll cream A in the short term organ culture experiments
performed as described above were analysed, EGCG was
detected at low concentrations. EGCG was detected after
1 h at 0.17 lg/ml in the citrate phosphate extraction buffer,
peaking at 0.29 lg/ml after 4 h, and was detectable up to
48 h after dosage. EGC, EC and ECG were not detected in
the tissue, and no GTCs were detected in the culture media
over 48 h.
Histology
Tissue biopsies were removed from the whole tissue organ
culture model, washed and photographed prior to pro-
cessing (Fig. 5). After 10 days, there was no observable
difference in tissue morphology, size, integrity or skin
colour between the untreated controls and the treated
samples. Tissue morphology over the 10 day culture period
Fig. 4 Details of the HPLC
calibration experiments
performed. a An example HPLC
trace, indicating the resolution
of the EGC (*5.5 min), EC
(*11.3 min) and EGCG
(*13.1 min) peaks observed in
a mixed calibration curve
sample. Pure GTC compounds
were solubilised separately, and
following serial dilution were
injected at increasing
concentrations. ECG peak
at *37 min is not shown due to
scale. b An example calibration
curve for EGCG (n = 6
separate calibration curves), the
most commonly found and
bioreactive GTC found in
C. sinensis. c Characteristics of
the individual GTC HPLC
calibration curves (n = 6),
indicating the reproducibility
and linearity of the protocol and
methodology
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was further investigated using haematoxylin and eosin
staining (Fig. 6). There was little difference in epidermal
cell layer thickness between day 0, day 3, day 7 and day 10,
however there was some swelling of the stratum corneum
layer in the cultured samples over time. There was no
difference in morphology between the different green tea
formulations, nor between the treated and untreated
controls.
Protein expression in the long term organ culture model
was determined using histology, and quantified using the
Definiens Tissue Studio software suite. An untreated
biopsy taken at day 0 was used as a starting control, while
Fig. 5 Photographs of 6 mm
punch biopsies removed from
whole tissue organ culture
experiments after 3, 7 and
10 days, for treated samples and
untreated controls. After
10 days, there was no
observable difference in tissue
morphology, size, integrity or
skin colour between the
untreated controls and the
treated samples. Scale bar
1 mm
Fig. 6 Immunohistological
analysis of tissue morphology in
an organ culture model using
hematoxylin and eosin (H and
E) staining. Day 0, Day 3, Day 7
and Day 10 untreated biopsies
(no formulation used) were
included as a control. There was
little difference in epidermal
cell layer thickness between day
0, day 3, day 7 and day 10, nor
in morphology between the
different green tea formulations
and the treated and untreated
controls. Scale bar = 200 lm
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an untreated biopsies taken from the organ culture model
after 3, 7 and 10 days were also used as an internal control.
Target proteins were mast cell tryptase (Fig. 7) and mast
cell chymase (Fig. 8). Both mast cell tryptase and mast cell
chymase were detected in the treated biopsies after 3, 7 and
10 days, and were quantified with respect to control tissues
by fluorescence or peroxidise staining intensity and cell
count, normalised with respect to area to give a density.
For both mast cell tryptase and mast cell chymase, the
highest cell density and fluorescence density were observed
at day 0. There was a reduction in cell count and fluores-
cence density in 3, 7 and 10 day treated and untreated
Fig. 7 Immunohistological
analysis of mast cell tryptase
protein expression. Day 0, Day
3, Day 7 and Day 10 untreated
biopsies (no formulation used)
were included as a control. Mast
cell numbers were reduced in
Cream A and Cream C after 7
and 10 days, compared with
treated and untreated controls.
Scale bar = 200 lm
Fig. 8 Immunohistological
analysis of mast cell chymase
expression in an organ culture
model using peroxidise staining.
Day 0, Day 3, Day 7 and Day 10
untreated biopsies untreated
biopsies (no formulation used)
were included as a control. Mast
cell numbers were reduced in
cream A and cream C after 7
and 10 days, compared with
treated and untreated controls.
Scale bar = 200 lm
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controls compared with the day 0 control, however this was
not significant. There was a further reduction in mast cell
tryptase and mast cell chymase expression in the treated
biopsies after 3, 7 and 10 days compared with the respec-
tive treated and untreated controls at the same time point
(p\ 0.05 at day 7 and 10). However there was no dis-
cernible difference between the two treatment
formulations.
Discussion
When treated samples were compared to their respective
treated controls, there was reduced gene expression of a-
SMA, fibronectin, mast cell tryptase, mast cell chymase,
TGF-b1, CTGF and PAI-1. Histological data has shown
that the tissue biopsies maintain their structure and integ-
rity up to 10 days when treated, and that mast cell numbers,
as quantified by mast cell chymase and tryptase staining,
are reduced compared with both treated and untreated
controls and compared with day 0 (p\ 0.05). The differ-
ences in gene expression observed between the two cream
formulations may be attributed to the additional active
ingredients between the two formulations. Formulation 1
(Cream A and B) contained Hydrolysed Algin, Chlorella
Vulgaris, Magnolia Officinalis Bark Extract and Vitis
Vinifera Seed Extract, whereas formulation 2 (Cream C
and D) contained Aloe Barbadensis Leaf Juice, Tocopherol
and Sodium Hyaluronate, all of which are commonly used
in cosmetics as moisturising agents (Table 1). In addition,
formulation 1 contained 5 % Camellia sinensis extract,
whereas formulation two contained 5 % EGCG. As dis-
cussed earlier in the results, EGCG is the main active
catechin present in C. sinensis extract and has the highest
anti-oxidant activity due to the number of hydroxyl groups
present in its structure [29, 36], this is metabolized to EGC
and ECG metabolized to EC [40], which guided our
decision to use EGCG in the second topical formulation.
The use of ex vivo whole skin biopsies in culture allows
the effect of individual ingredients and formulations to be
tested [33], and a number of different approaches exist.
Utilising a collagen matrix embedding protocol, skin
biopsies are fixed in culture plates [1, 12]. In work previ-
ously published by our group, green tea catechins were
shown to inhibit keloid tissue growth and induce biopsy
shrinkage using the collagen embedding methodology, also
indicating altered expression of many of the markers
identified and chosen for this study [38]. In the modified
approach used in this study, transwell inserts containing a
fine mesh bottom are used to suspend the biopsy in culture
media [27]. This has the added benefit of keeping the
epidermis exposed, allowing for topical treatments to be
applied.
The health benefits and anti-oxidant activity of C. si-
nensis have been known for centuries [29, 36], reducing the
potential damaging effect of reactive oxygen species and
free radicals, as well as inhibiting cell signalling pathways
linked to cancer, inflammation and autoimmune disease [4,
19, 20, 25, 41, 42]. The amount of catechins present in
green tea can vary dependant on batch, number of cups
drank daily and brew strength, with catechins degrading
when brewed due to temperature [5, 21]. Transdermal
delivery avoids some of the issues associated with oral
delivery, such as first pass metabolism in the liver and
gastrointestinal uptake of molecules, with localized dosage
targeting the skin [14, 21].
Topical applications of GTCs have been shown to have
a beneficial effect on a range of pathways in different
models. In an artificial skin culture model GTC decreased
the level of MMPs production and increased TIMP-1
expression level, and reduced alterations in the extracel-
lular matrix following application of UVA radiation [25].
A comparable UVA/UVB radiation study undertaken in a
mouse model using EGCG and ginkgo biloba showed that
the two extracts had a complimentary photoprotective
effect, linked to a biological/free radical scavenging effect
as opposed to a UV-filtering effect [7]. GTCs also play a
role in angiogenesis. In a small scale double blind clinical
study in human subjects suffering from erythema and
telangiectasia, catechin containing topical treatment
reduced both HIF-1 alpha and VEGF expression [10]. In a
separate study in aged skin, a combination of oral green tea
and topical cream increased skin elastic tissue content [6].
It has been shown that GTCs significantly inhibit mast
cell stimulated type I collagen expression by suppressing
activation of the PI-3k/Akt/mTOR signalling pathways in
keloid fibroblast culture [43]. High concentrations of
EGCG reversibly regulated the cell growth and expression
of cell cycle-related proteins and genes in normal fibrob-
lasts, inhibiting cancer cell line proliferation while leaving
normal cells unaffected at an appropriate dosage [15].
EGCG suppresses keloid fibroblast pathogenesis by
inhibiting STAT3 signalling, but that although EGCG
inhibited PI3K and MEK/ERK signalling, did not further
block proliferation, migration, or collagen production in
KFs treated with STAT3 inhibitors [31].
We also demonstrated that topical cream formulations
containing GTC reduces mast cell numbers in a normal
skin organ culture model. This finding has implications for
the treatment of a range of mast cell influenced skin dis-
orders, such as contact dermatitis, atopic dermatitis, pso-
riasis and scleroderma where number of mast cells are
increased [3, 17, 23, 26, 30, 39]. We have shown that GTC
from different cream formulations delivered to the stratum
corneum of normal human skin are retained in the skin,
consistent with previously published findings. GTCs fit the
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profile for being suitable for transdermal delivery [37], and
have previously been analysed in mouse pig and human
skin models, with differing rates of uptake through the
stratum corneum into the epidermis and dermis in each
animal model [2, 8, 13, 24]. Further long term clinical
studies in normal and diseased human skin are required in
order to establish the efficacy and utility of this therapeutic
approach.
In conclusion, this skin model can be utilised as a further
tool alongside already established cell culture based mod-
els to analyse not only cosmaceuticals and transdermal
delivery, but can also be adapted to study skin biopsies
taken from a range of conditions in order to assess wound
healing mechanisms, fibrosis or other skin diseases. This
approach may also prove a useful tool in the future
development of new cosmeceuticals and understanding
disease alongside already established techniques, in order
to give a further level of validation to the data produced
whilst avoiding the need for using animal models.
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